The aim of the Familial Cancer Risk Core is to offer a unique resource to obtain clinical samples and data for Cancer Center members who study hereditary cancer syndromes and high-risk families. Investigations of this cancer susceptible population encompass epidemiology, behavioral and health policy aspects, basic science, and clinical trials of treatment and prevention. As of August 2001, the Core has registered 1500 subjects at increased risk for cancer, of whom over 700 have agreed to provide clinical data, DNA, and tissue for research purposes through IRB-approved protocols. Over half of these subjects have been specifically genotyped for hereditary cancer gene mutations. Located at the Mount Zion Hospital and UCSF Cancer Clinic Building (with a satellite clinic in Sacramento), the Familial Cancer Risk Core is administered directly by the Cancer Center. Clinical services provide an assessment of individual cancer risk within families that display a hereditary cancer pattern in order to minimize the risk of cancer. As a shared resource, the Core will provide the following services to the Cancer Center members: (1) clinical genetic expertise for pedigree building and verification, investigation of familial genetic syndromes, and research of germline mutations and cancer modifier genes; (2) access to a database of genotyped subjects with hereditary cancer for identification of patient subsets and suitable controls; (3) availability of clinical specimens (DNA, tissue) with correlative clinical and epidemiological data and clinical outcomes from probands and families with genetically verified hereditary cancer; (4) availability of cancer families for clinical trials of early cancer detection and prevention, as well as opportunities for ethical, health policy, behavioral, and psychosocial research; and (5) clinical genetic services and an educational website that can speed translational genetic discoveries (e.g. modifier genes) to clinical application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082103-04
Application #
6694327
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-09-27
Project End
2007-01-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications